The patent approval strengthens the company’s intellectual property portfolio and represents an important milestone ahead of the international PCT application planned for spring 2026. The antimicrobial mechanism is a central component of the M045A technology and is considered to be of great importance in the pursuit of an effective treatment for recurrent oral ulcers caused by aphthae.
M045A is based on a dual-action principle that combines hygroscopic moisture absorption with an innovative antimicrobial effect. By reducing moisture in the wound environment, conditions are created that strongly inhibit microbial growth, which may contribute to faster symptom relief and improved healing conditions.
“The Swedish patent approval is an important validation of our work,” says Professor Mats Jontell. “The antimicrobial effect addresses a crucial part of the problem surrounding oral ulcers caused by aphthae and brings us closer to a more effective treatment.”
Project Manager Jean Lycke adds:
“The patent approval gives us a solid foundation to build upon. The technology has great potential, not only for aphthae, but also in other areas where the combination of hygroscopy and antimicrobial action can provide significant clinical benefits.”
The Swedish patent approval thus constitutes a significant milestone in Mucocort AB’s continued efforts to develop innovative solutions for improved oral health.
Mucocort is part of and receives business support from Umeå Biotech Incubator.
For more info, please contact:
Jean Lycke, project manager, Mucocort AB
Tele: 070-277 15 11
Email: jl@emerentiagruppen.com